Two Sigma Advisers’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Two Sigma Advisers’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,468	Closed	-$45K	–	2802
2022 Q3	$45K	Buy	+10,468	New	+$57.3K	﹤0.01%	2382
2022 Q2	–	Sell	-1,568	Closed	-$14K	–	3010
2022 Q1	$14K	Buy	1,568 +72	+5%	+$685	﹤0.01%	2684
2021 Q4	$17K	Buy	+1,496	New	+$21.5K	﹤0.01%	2554
2021 Q1	–	Sell	-2,364	Closed	-$48K	–	2810
2020 Q4	$48K	Buy	+2,364	New	+$46.3K	﹤0.01%	2324

Other funds holding NVIV

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Two Sigma Advisers's NVIV Position: Q4 2022 in Review

Two Sigma Advisers sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2022, closing a stake of 10,468 shares — an estimated $45K sold.

Two Sigma Advisers first reported a position in NVIV in Q4 2020 and held it in 4 quarters. The position peaked at $48K in Q4 2020. 18 funds tracked by Wall St. Rank hold NVIV as of Q4 2022.

Two Sigma Advisers reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2022 after selling out during the quarter.
Two Sigma Advisers sold 10,468 InVivo Therapeutics Holdings Corp shares in Q4 2022, an estimated $45K.
Two Sigma Advisers first reported a position in InVivo Therapeutics Holdings Corp in Q4 2020 and held it in 4 quarters.
Two Sigma Advisers's InVivo Therapeutics Holdings Corp position peaked at $48K in Q4 2020.
18 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.